W

ASHINGTON — Two weeks ago, Dr. Joseph Gulfo ran a panel at the Biotech Showcase in San Francisco titled, “The Trump Administration: What to expect from the FDA.”

He left out one key detail: He may end up running the place.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Gulfo would be a terrific choice. He’s knowledgeable, has long experience in both academic and industry, and has the fire in the belly for reform.

  • What is his position on device approvals and safety? Would he keep the current outdated “one type fits all” system, or move to a framework for Precision Devices, with prescreening patients for immune reactivity to determine if device materials are “right for you” before being installed?

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.